metformin has been researched along with Infant, Small for Gestational Age in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Infant, Small for Gestational Age: An infant having a birth weight lower than expected for its gestational age.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin." | 9.51 | Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022) |
| "Metformin has been used in pregnancy since the 1970s." | 9.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "In this study, we observed a high percentage of SGA births among women with type 2 diabetes and chronic hypertension and/or nephropathy who were treated with metformin." | 5.51 | Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin? ( Asztalos, E; Donovan, LE; Feig, DS; Murphy, KE; Sanchez, JJ; Shah, PS; Tomlinson, G; Zinman, B, 2022) |
| "This is a randomized double-blind multi-center clinical trial of insulin plus metformin versus insulin plus placebo for the treatment of type 2 diabetes complicating pregnancy." | 5.27 | Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study. ( Berry, DC; Boggess, K; de Los Angeles Abreu, M; Dorman, KF; Ivins, AR; Thomas, SD; Young, L, 2018) |
| "Metformin has been used in pregnancy since the 1970s." | 5.22 | Metformin for pregnancy and beyond: the pros and cons. ( Dunne, FP; Newman, C, 2022) |
| "To determine how glucose control in women with GDM treated with metformin and/or insulin influenced pregnancy outcomes." | 5.14 | Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. ( Gao, W; Hague, WM; McIntyre, HD; Rowan, JA, 2010) |
| "Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy." | 1.62 | Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. ( Brownfoot, F; Cannon, P; Cruickshank, T; Garcha, D; Hannan, NJ; Hyett, J; Illanes, SE; Jellins, J; Kaitu'u-Lino, TJ; Kandel, M; Keenan, E; MacDonald, TM; Masci, J; Middleton, A; Murphy, C; Murray, E; Myers, J; Nguyen, TV; Nien, JK; Pell, G; Pritchard, N; Roddy Mitchell, A; Schepeler, M; Tong, S; Walker, SP; Whigham, CA; Wong, GP, 2021) |
"Metformin treatment was accompanied by a drop in fasting insulin and serum androgens and by a less atherogenic lipid profile (all P | 1.31 | Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. ( De Zegher, F; Ferrer, A; Ibáñez, L; Marcos, MV; Potau, N; Rodriguez-Hierro, F, 2002) | |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Newman, C | 1 |
| Dunne, FP | 1 |
| Feig, DS | 1 |
| Zinman, B | 1 |
| Asztalos, E | 1 |
| Donovan, LE | 1 |
| Shah, PS | 1 |
| Sanchez, JJ | 1 |
| Tomlinson, G | 1 |
| Murphy, KE | 1 |
| Garcha, D | 1 |
| Walker, SP | 1 |
| MacDonald, TM | 1 |
| Hyett, J | 1 |
| Jellins, J | 1 |
| Myers, J | 1 |
| Illanes, SE | 1 |
| Nien, JK | 1 |
| Schepeler, M | 1 |
| Keenan, E | 1 |
| Whigham, CA | 1 |
| Cannon, P | 1 |
| Murray, E | 1 |
| Nguyen, TV | 1 |
| Kandel, M | 1 |
| Masci, J | 1 |
| Murphy, C | 1 |
| Cruickshank, T | 1 |
| Pritchard, N | 1 |
| Hannan, NJ | 1 |
| Brownfoot, F | 1 |
| Roddy Mitchell, A | 1 |
| Middleton, A | 1 |
| Pell, G | 1 |
| Wong, GP | 1 |
| Tong, S | 1 |
| Kaitu'u-Lino, TJ | 1 |
| Aiken, CEM | 1 |
| Hone, L | 1 |
| Murphy, HR | 1 |
| Meek, CL | 1 |
| Berry, DC | 1 |
| Thomas, SD | 1 |
| Dorman, KF | 1 |
| Ivins, AR | 1 |
| de Los Angeles Abreu, M | 1 |
| Young, L | 1 |
| Boggess, K | 1 |
| Rowan, JA | 2 |
| Luen, S | 1 |
| Hughes, RC | 1 |
| Sadler, LC | 1 |
| McCowan, LM | 1 |
| Gao, W | 1 |
| Hague, WM | 1 |
| McIntyre, HD | 1 |
| Boguszewski, MC | 1 |
| Mericq, V | 1 |
| Bergada, I | 1 |
| Damiani, D | 1 |
| Belgorosky, A | 1 |
| Gunczler, P | 1 |
| Ortiz, T | 1 |
| Llano, M | 1 |
| Domené, HM | 1 |
| Calzada-León, R | 1 |
| Blanco, A | 1 |
| Barrientos, M | 1 |
| Procel, P | 1 |
| Lanes, R | 1 |
| Jaramillo, O | 1 |
| Ibáñez, L | 3 |
| Potau, N | 1 |
| Ferrer, A | 1 |
| Rodriguez-Hierro, F | 1 |
| Marcos, MV | 1 |
| De Zegher, F | 2 |
| Fucci, A | 1 |
| Valls, C | 1 |
| Ong, K | 2 |
| Dunger, D | 1 |
| Dunger, DB | 1 |
| Zegher, Fd | 1 |
| Homburg, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy[NCT02932475] | Phase 3 | 831 participants (Actual) | Interventional | 2017-05-25 | Terminated (stopped due to Recommendation by the DSMB that the study be stopped for futility) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neonatal fat mass measured by skin-fold thickness (anthropometrics).The circumference of the upper limb is the circumference of the upper arm, and the circumference of the lower limb equals the mean of the circumferences measured at the midthigh and calf. The volume of the subcutaneous layer of fat covering each cylinder is estimated by multiplying the length times the circumference times the layer of fat estimated by the skinfold measures. The triceps skinfold measure is used as an estimate of the fat thickness of the limbs, and the subscapular skinfold measure approximates the fat thickness of the trunk. Total body fat is estimated by summing the volumes of fat covering each of the cylinders and multiplying by 0.9 (the density of fat). (NCT02932475)
Timeframe: Within 72 hrs of birth
| Intervention | kg (Mean) |
|---|---|
| Maternal Metformin | 0.46 |
| Maternal Placebo | 0.5 |
"Participants with one or more of the following:~capillary blood glucose level of < 30 mg/dL or capillary blood glucose requiring medical treatment, or~Birth trauma (umbilical cord artery pH < 7.0 or shoulder dystocia with brachial plexus injury), or~Hyperbilirubinemia requiring phototherapy, or~Deliver < 37 weeks' gestation, or~Miscarry, are stillborn, experience a neonatal demise, or~Large for gestational age infant (birth weight > 90th percentile for gestational age), or~Small for gestational age infant (birth weight < 10th percentile for gestational age) or low birth weight (< 2500 gm)" (NCT02932475)
Timeframe: An average of 48 hours for term infants and 30 days for preterm infants
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin | 269 |
| Placebo | 277 |
Adverse maternal outcomes. (NCT02932475)
Timeframe: An average of 48 hours following delivery
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Any adverse event leading to early study agent discontinuation | Any adverse event associated with maternal death | Any adverse event associated with fetal death | Any maternal serious adverse event | Any maternal non-serious adverse event | |
| Metformin | 13 | 2 | 10 | 113 | 149 |
| Placebo | 20 | 1 | 10 | 111 | 157 |
Adverse neonatal outcomes (NCT02932475)
Timeframe: up to 28 days of life
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any neonatal serious adverse event | Any neonatal non-serious adverse event | |
| Maternal Metformin | 81 | 157 |
| Maternal Placebo | 105 | 162 |
"Secondary outcome of maternal side effects were defined as:~clinically relevant hypoglycemia defined as capillary blood glucose < 60 or < 80 with symptoms~GI side effects defined as nausea, vomiting, diarrhea" (NCT02932475)
Timeframe: Throughout study until delivery at 40 weeks gestation
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Clinically relevant hypoglycemia | Gastrointestinal side effects | |
| Metformin | 87 | 182 |
| Placebo | 85 | 171 |
2 reviews available for metformin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Metformin for pregnancy and beyond: the pros and cons.
Topics: Administration, Oral; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational W | 2022 |
Pregnancy complications in PCOS.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperinsulinism; Hypertension, Pregnan | 2006 |
4 trials available for metformin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Hyp | 2022 |
Rationale, design, and methods for the Medical Optimization and Management of Pregnancies with Overt Type 2 Diabetes (MOMPOD) study.
Topics: Adolescent; Adult; Birth Injuries; Diabetes Mellitus, Type 2; Disease Management; Double-Blind Metho | 2018 |
Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial.
Topics: Birth Weight; Diabetes Complications; Diabetes, Gestational; Female; Gestational Age; Glucose Tolera | 2010 |
Neutrophil count in small-for-gestational age children: contrasting effects of metformin and growth hormone therapy.
Topics: Child; Human Growth Hormone; Humans; Infant, Newborn; Infant, Small for Gestational Age; Leukocyte C | 2005 |
6 other studies available for metformin and Infant, Small for Gestational Age
| Article | Year |
|---|---|
Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Topics: Adult; Area Under Curve; Birth Weight; Cell Hypoxia; Delivery, Obstetric; Diabetes, Gestational; Ele | 2021 |
Improving outcomes in gestational diabetes: does gestational weight gain matter?
Topics: Adult; Body Mass Index; Delivery, Obstetric; Diabetes, Gestational; Female; Fetal Macrosomia; Gestat | 2019 |
Customised birthweight centiles are useful for identifying small-for-gestational-age babies in women with type 2 diabetes.
Topics: Adult; Birth Weight; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2009 |
Latin American consensus: children born small for gestational age.
Topics: Child, Preschool; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female | 2011 |
Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism.
Topics: Abdomen; Adolescent; Anovulation; Body Composition; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2002 |
Effects of growth hormone treatment on neutrophil count in children born small for gestational age.
Topics: Child; Growth Disorders; Human Growth Hormone; Humans; Hypoglycemic Agents; Infant, Newborn; Infant, | 2006 |